Northland named TriSalus Life Sciences (TLSI) as the analyst’s Top Pick for 2026 with an Outperform rating and $12.50 price target on the shares. The firm see TriSalus’ TriNav franchise emerging as a best-in-class platform for embolization procedures and expects continued market share gains in TACE and TARE procedures in the near-term, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- Expanding Indications and Diversified Revenue Base Support Buy Rating on TriSalus Life Sciences
- TriSalus Life Sciences price target raised to $12 from $11 at Canaccord
- TriSalus Life Sciences: Strong Growth Prospects and Strategic Developments Reinforce Buy Rating
- TriSalus Life Sciences: Strong Revenue Growth and Strategic Initiatives Drive Buy Rating
- Trisalus Life Sciences Reports Strong Earnings Amid Challenges